Clinical Trial Update: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years [Phase 3]

View source ↗

Summary

A Phase 3 pediatric trial assessing safety and efficacy of tenapanor for irritable bowel syndrome with constipation (IBS-C) in patients aged 12 to under 18.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome with Constipation

Drugs mentioned

• Tenapanor (tenapanor)

Snippet

Sponsor: Ardelyx | Conditions: Irritable Bowel Syndrome With Constipation (IBS-C) | Phase 3 | Status: ACTIVE_NOT_RECRUITING